Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

Pricing
Back to journals
Academic Journal

Lancet

2 Papers Indexed in Blossom

Published Papers

Paywallmeta

Quality of reporting on psychological interventions in psychedelic treatments: a systematic review

This systematic review (s=45) on psychedelic-assisted psychotherapy for mental disorders finds that psychological interventions are reported with low completeness and high heterogeneity. It also finds that MDMA studies are more homogeneous, with greater procedural detail.

Published
December 9, 2024
Journal
Lancet
Authors
Seybert, C., Schimmers, N., Silva, L., Breeksema, J. J., Veraart, J. K. E., Bessa, B. S., d'Orsi, D., Schoevers, R. A., Dinis-Oliveira, R. J.
Paywallmeta

The therapeutic potential of psychedelics: the European regulatory perspective

This commentary (2023) showcases the support, and open questions, from the European regulatory perspective. It highlights the difficulties facing psychedelic trials (e.g. blinding), and showcases the support EMA can offer in ensuring the trials get done in a way that will lead to regulatory approval.

Published
February 10, 2023
Journal
Lancet
Authors
Butlen-Ducuing, F., McCulloch, D. E-W., Haberkamp, M., Mattila, T., Bałkowiec-Iskra, E., Aislaitner, G., Balabanov, P., Lundberg, J., Stenbæk, D. S., Elferink, A., Knudsen, G. M., Thirstrup, S.

Quick Facts

Papers Indexed
2
Publisher
Elsevier
Website
Visit

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.